The Drug Abuse Screening Test (DAST): First 40 Years and Future Developments DOI
Harvey A. Skinner, Sarah Samadi,

Sirkhail Khan

et al.

The Canadian Journal of Addiction, Journal Year: 2024, Volume and Issue: 15(4), P. 6 - 13

Published: Dec. 1, 2024

ABSTRACT Since the original article was published over 40 years ago, Drug Abuse Screening Test (DAST) developed at Centre for Addiction and Mental Health—CAMH, Toronto (www.camh.ca/) has become one of most widely used addiction instruments in North America internationally population clinical screening, assessment, research a broad range settings. The developmental prototype contained 28 items (DAST-28) from which 2 versions were derived: 10-item DAST-10 screening more comprehensive 20-item DAST-20 assessment research. first aim this commentary review is to highlight recent trends wide-ranging use on DAST. international reach exemplified by 18 (currently) translations cultural adaptations. Research shown that DAST exhibits high levels reliability validity across public health settings, it as benchmark validation studies other measures. recommended instrument national agencies an evidence-based tool, example, https://cde.nida.nih.gov/. To address evolving contextual shifts, especially imperative reduce stigma, second introduce revised designated DAST-10-R DAST-20-R, incorporate recommendations NIDA’s (2021) Words Matter—Terms Use Avoid When Talking About Addiction. A feasibility study described community center. Future directions are outlined, including calibration DAST-R with evaluating utilization spectrum health, community, Depuis la publication de l’article il y plus ans, le mis au point par Health - CAMH, est devenu l’un des les utilisés en Amérique du Nord et dans monde pour dépistage, l'évaluation recherche milieu clinique un large éventail contextes. Le développement contenait à partir desquels deux ont été dérivées : 10 dépistage 20 items, complet, recherche. premier objectif ce commentaire mettre évidence tendances récentes l’utilisation grande échelle La portée internationale illustrée ses traductions (actuelles) adaptations culturelles. montré que présente niveaux élevés fiabilité validité toute une série contextes cliniques santé publique, qu’il utilisé comme référence études d’autres mesures. recommandé agences nationales tant qu’outil fondé sur données probantes exemple, Pour tenir compte l'évolution contexte, particulier l’impératif réduction stigmatisation, deuxième présenter révisées désignées qui intègrent recommandations rapport NIDA Matter Terms . Une étude faisabilité centre communautaire décrite. Les orientations futures sont présentées, compris l'étalonnage avec travers spectre communauté environnements cliniques.

Language: Английский

Primary crime-related outcome indicators associated with recreational cannabis legalization: a comprehensive literature and data review DOI
Benedikt Fischer, Tessa Robinson, Hans‐Jörg Albrecht

et al.

Crime Law and Social Change, Journal Year: 2024, Volume and Issue: 82(3), P. 685 - 715

Published: July 23, 2024

Language: Английский

Citations

2
Commentary: The Conflict Between Protecting Public Health and Raising Tax Revenue DOI
Wayne Hall

Healthcare policy, Journal Year: 2024, Volume and Issue: 19(3), P. 29 - 32

Published: Feb. 28, 2024

When Canada created a legal market for cannabis, it gave priority to public health by restricting marketing using branding and promotion via social other media sources. These restrictions protect the from harmful use are under increasing pressure cannabis industry, which claims that they prevent them outcompeting replacing illicit market. Public advocates reasonably concerned these will not hold given our experience with alcohol, tobacco gambling where governments' fiscal dependence on tax revenue favours liberalization of regulation.

Language: Английский

Citations

2
Die Legalisierung von Cannabis in Deutschland DOI Creative Commons

Hanno Beck,

Aloys Prinz

Wirtschaftsdienst, Journal Year: 2024, Volume and Issue: 104(2), P. 128 - 135

Published: Feb. 1, 2024

Abstract The federal government has presented a draft law to legalise the controlled use of cannabis, known as Cannabis Act (CanG). What does this regulate and how is it expected affect cannabis use? Is there empirical evidence support expectations? will determine whether objectives can be achieved or not? This article describes main provisions criticism also examines possible consequences with view literature.

Language: Английский

Citations

0
Examining Safer Opioid Supply Policies DOI

Owen J. Chen,

Xi Zhang, Julia Xiao Xuan Luo

et al.

JAMA Internal Medicine, Journal Year: 2024, Volume and Issue: 184(7), P. 846 - 846

Published: May 6, 2024

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals Network Open Cardiology Dermatology Health Forum Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2024 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal

Language: Английский

Citations

0
TheCannabis Act: implications for human participant research with cannabis DOI Open Access
Patricia Di Ciano, Christine M. Wickens,

Elvin M. Paul

et al.

Journal of Psychiatry and Neuroscience, Journal Year: 2024, Volume and Issue: 49(3), P. E212 - E217

Published: June 18, 2024

In Canada, cannabis was legalized for medical purposes in 2001 and nonmedical use 2018, with edibles, concentrates, topicals following 2019 under the Canadian Cannabis Act (Bill C-45).[1][1] This legislation regulates production, distribution, sale, possession of cannabis,

Language: Английский

Citations

0
Should cannabis self-cultivation be part of a public health‒oriented legalization policy framework? DOI
Benedikt Fischer, Tessa Robinson

Can J Public Health, Journal Year: 2024, Volume and Issue: 115(5), P. 784 - 788

Published: July 24, 2024

Language: Английский

Citations

0
Quality of life and cannabis use among patients with drug‐resistant epilepsy—An observational study from a Canadian tertiary care referral center DOI Creative Commons
Kanika Jhanji, Zaitoon Shivji,

Marion Lazaj

et al.

Epileptic Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 5, 2024

Abstract Objective Very few publications have reported the impact of artisanal cannabis use on overall quality life among people with drug‐resistant epilepsy. This study aimed to evaluate association adults epilepsy life, and determine if an exists between Quality‐of‐Life in Epilepsy Inventory‐31 (QOLIE‐31) ‘T scores’ different clinical variables. Methods included patients admitted a Canadian tertiary care center as part larger study. These were confirmed by epileptologist at Ambulatory Clinic. Patients categorized into users (CAN group) ( n = 25) Non‐cannabis (Non‐CAN 21). Data was collected RedCap® for details. analyzed using binary multivariable logistic regression model QOLIE‐31 age, sex, duration, age initiation use, duration psychiatric related comorbidity all patients. Additionally, subscores’ questionnaire compared CAN group Non‐CAN group. Results A statistically significant difference T subscore ‘energy fatigue’ p .004) found, scoring higher. However, ‘overall score’ two groups there no statically .11). negative correlation disorder .032) found. Significance provides new data can serve foundation future studies better assess this association.

Language: Английский

Citations

0
Changes in Cannabis-Related Health Care Use in Alberta After Cannabis Legalization Between 2018 and 2022: A Population-Based Interrupted Time Series Study DOI
Mohammad Habibullah Pulok, Nirav P. Patel,

Michelle Fry

et al.

International Journal of Mental Health and Addiction, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

Citations

0
Nonmedical cannabis legalization policy in Canada: Has commercialization been a pivotal mistake for public health? DOI Creative Commons
Benedikt Fischer, Wayne Hall, Didier Jutras‐Aswad

et al.

World Medical & Health Policy, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 25, 2024

Abstract Canada implemented the legalization of nonmedical cannabis use and supply in 2018. Initial blueprints for policy framework emphasized public health protection as a priority principle objective, including related design parameters regulatory restrictions (e.g., strict access distribution control, advertisement/promotion ban, etc.) also informed by adverse experiences from alcohol/tobacco control. Conversely, Canada's present ecology is characterized increasingly far‐reaching commercialization; this includes an extensive for‐profit production retail industry producing large sales volumes that centrally include high‐risk products, with many health‐oriented provisions hollowed out or circumvented practice. While key cannabis‐related problem indicators have increased through legalization, mounting evidence suggests these outcome dynamics, to crucial extent, been accelerated commercialization aspects legalization. Meanwhile, since has pushed further rollbacks benefits competitiveness. Using Canadian case study, we focus on possible pitfalls effects dynamics Also commercialization‐related developments outcomes are hard reverse, urge jurisdictions planning reforms carefully take consider when assembling their frameworks.

Language: Английский

Citations

0
Impacts and Implications of Cannabis Legalization on Key Outcomes Among Adolescents in Canada DOI Creative Commons
Tessa Robinson, Didier Jutras‐Aswad, Benedikt Fischer

et al.

The Canadian Journal of Psychiatry, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 25, 2024

Language: Английский

Citations

0